Clinical practice guideline: Hoarseness (Dysphonia)

Release Date · September 2009 **Guideline Developer** · American Academy of Otolaryngology–Head and Neck Surgery Foundation **INTENDED AUDIENCE** Users · All clinicians who are likely to diagnose and manage patients with hoarseness **Care Setting** · Any setting in which hoarseness would be identified, monitored, treated, or managed **TARGET POPULATION** Eligibility The target patient for this guideline is anyone presenting with hoarseness (dysphonia). **Inclusion Criterion** · Hoarseness (dysphonia) **Exclusion Criterion** · History of laryngectomy (total or partial) · Craniofacial anomalies · Velopharyngeal insufficiency

• Dysarthria (impaired articulation)

KNOWLEDGE COMPONENTS

DEFINITIONS

RECOMMENDATION: STATEMENT 1. DIAGNOSIS

Conditional:	Clinicians should diagnose hoarseness (dysphonia) in a patient with altered voice quality, pitch, loudness, or vocal effort that impairs communication or reduces voice-related QOL {quality of life}.
	Decision Variable: patient with altered voice quality
	Decision Variable: patient with altered pitch
	Decision Variable: patient with altered loudness
	Decision Variable: patient with altered vocal effort
	Decision Variable: impairs communication
	Decision Variable: reduces voice-related QOL {quality of
	life}
	Action: Clinicians should diagnose hoarseness (dysphonia)
	Benefit: Identify patients who may benefit from
	treatment or from further investigation to identify
	underlying conditions that may be serious
	Benefit: promote prompt recognition and treatment
	Benefit: discourage the perception of hoarseness as a trivial condition that does not warrant attention
	urviar condition that does not warrant attention

Risk/Harm: Potential anxiety related to diagnosis **Evidence Quality:** Grade C

Recommendation Strength: Recommendation based on observational studies with a preponderance of benefit over harm

Logic: If (patient with altered voice quality OR patient with altered pitch OR patient with altered loudness OR patient with altered vocal effort) AND (impairs communication OR reduces voice-related QOL {quality of life}) Then Clinicians should diagnose hoarseness (dysphonia) **Cost:** Cost: Time expended in diagnosis, documentation, and discussion

RECOMMENDATION: STATEMENT 2. MODIFYING FACTORS

Imperative: Clinicians should assess the patient with hoarseness by history and/or physical examination for factors that modify management such as one or more of the following: recent surgical procedures involving the neck or affecting the recurrent laryngeal nerve, recent endotracheal intubation, radiation treatment to the neck, a history of tobacco abuse, and occupation as a singer or vocal performer.
Directive: Clinicians should assess the patient with

hoarseness by history for factors that modify management

Description: factors that modify management such as one or more of the following: recent surgical procedures involving the neck or affecting the recurrent laryngeal nerve, recent endotracheal intubation, radiation treatment to the neck, a history of tobacco use, and occupation as a singer or vocal performer **Benefit:** To identify factors early in the course of management that could influence the timing of diagnostic procedures, choice of interventions, or provision of follow-up care

Risk/Harm: None

Directive: Clinicians should assess the patient with hoarseness by physical examination for factors that modify management

Description: factors that modify management such as one or more of the following: recent surgical procedures involving the neck or affecting the recurrent laryngeal nerve, recent endotracheal intubation, radiation treatment to the neck, a history of tobacco abuse, and occupation as a singer or vocal performer **Benefit:** To identify factors early in the course of management that could influence the timing of diagnostic procedures, choice of interventions, or

	provision of follow-up care
	Risk/Harm: None
	Evidence Ouality: Grade C
	Recommendation Strength: Recommendation based on
	observational studies with a preponderance of benefit over
	harm
	Logic: If (Inclusion Criterion: Hoarseness (dysphonia))
	Then Clinicians should assess the nationt with hourseness by
	history for factors that modify management OP Clinicians
	should assess the potient with hearseness by physical
	should assess the patient with hoarseness by physical
	Costs None
	Cost: None
RECOMMENDATIO	ON: STATEMENT 3A. LARYNGOSCOPY AND HOARSENESS
Imperative:	Clinicians may perform laryngoscopy, or may refer the
•	patient to a clinician who can visualize the larvnx, at any time
	in a patient with hoarseness.
	Directive: Clinicians may perform laryngoscopy at any time
	in a patient with hoarseness
	Benefit: Visualization of the larvnx to improve
	diagnostic accuracy and allow comprehensive
	evaluation
	Risk/Harm: Risk of larvngoscopy
	Risk/Harm: patient discomfort
	Directive: Clinicians may refer the patient to a clinician who
	can visualize the larvnx at any time in a patient with
	hoarseness
	Benefit: Visualization of the larvnx to improve
	diagnostic accuracy and allow comprehensive
	evaluation
	Risk/Harm: Risk of laryngoscopy
	Risk/Harm: patient discomfort
	Evidence Quality: Grade C
	Recommendation Strength: Option based on observational
	studies, expert opinion, and a balance of benefit and harm.
	Logic: If {Inclusion Criterion: Hoarseness (dysphonia) }.
	Then Clinicians may perform larvngoscopy at any time OR
	Clinicians may refer the patient to a clinicians who can
	visualize the larvnx at any time
	Cost: Procedural expense
RECOMMENDATIO	ON: STATEMENT 3B. INDICATIONS FOR LARYNGOSCOPY
Conditional:	Clinicians should visualize the patient's larvnx, or refer the
	patient to a clinician who can visualize the larvny, when
	hoarseness fails to resolve by a maximum of three months
	after onset, or irrespective of duration if a serious underlying

cause is suspected.

Decision Variable: hoarseness fails to resolve by a maximum of three months after onset

Decision Variable: a serious underlying cause is suspected. **Description:** irrespective of duration

Action: Clinicians should visualize the patient's larynx

Benefit: Avoid missed or delayed diagnosis of serious conditions in patients without additional signs or

symptoms to suggest underlying disease

Benefit: permit prompt assessment of the larynx when serious concern exists

Risk/Harm: Potential for up to a three-month delay in diagnosis

Risk/Harm: procedure-related morbidity

Action: Clinicians should refer the patient to a clinician who can visualize the larynx

Benefit: avoid missed or delayed diagnosis of serious conditions in patients without additional signs or

symptoms to suggest underlying disease

Benefit: permit prompt assessment of the larynx when serious concern exists

Risk/Harm: Potential for up to a three-month delay in diagnosis

Risk/Harm: procedure-related morbidity

Evidence Quality: Grade C

Recommendation Strength: Recommendation based on observational studies, expert opinion, and a preponderance of benefit over harm.

Flexibility: Intentional vagueness: The term "serious underlying concern" is subject to the discretion of the clinician. Some conditions are clearly serious, but in other patients, the seriousness of the condition is dependent on the patient. Intentional vagueness was incorporated to allow for clinical judgment in the expediency of evaluation **Logic:** If hoarseness fails to resolve by a maximum of three months after onset OR a serious underlying cause is suspected. Then Clinicians should visualize the patient's larynx OR Clinicians should refer the patient to a clinician who can visualize the larynx **Cost:** Procedural expense

RECOMMENDATION: STATEMENT 4. IMAGING

Conditional: Clinicians should not obtain computed tomography (CT) or magnetic resonance imaging (MRI) of the patient with a primary complaint of hoarseness prior to visualizing the larynx.

Decision Variable: patient with a primary complaint of hoarseness **Decision Variable:** prior to visualizing the larynx Action: Clinicians should not obtain computed tomography (CT) **Benefit:** Avoid unnecessary testing Benefit: minimize cost and adverse events Benefit: maximize the diagnostic yield of CT and MRI when indicated Cost: Cost: None Risk/Harm: Potential for delayed diagnosis Action: Clinicians should not obtain magnetic resonance imaging (MRI) **Benefit:** Avoid unnecessary testing Benefit: minimize cost and adverse events Benefit: maximize the diagnostic yield of CT and MRI when indicated Risk/Harm: Potential for delayed diagnosis Evidence Quality: Grade C Recommendation Strength: Recommendation against imaging based on observational studies of harm, absence of evidence concerning benefit, and a preponderance of harm over benefit **Logic:** If patient with a primary complaint of hoarseness AND prior to visualizing the larynx Then Clinicians should not obtain computed tomography (CT) AND Clinicians should not obtain magnetic resonance imaging (MRI) Cost: None

RECOMMENDATION: STATEMENT 5A. ANTI-REFLUX MEDICATION AND HOARSENESS.

Conditional:	Clinicians should not prescribe anti-reflux medications for
	patients with hoarseness without signs or symptoms of
	gastroesophageal reflux disease (GERD).
	Decision Variable: for patients with hoarseness
	Decision Variable: without signs of gastroesophageal reflux
	disease (GERD)
	Decision Variable: without symptoms of gastroesophageal
	reflux disease (GERD)
	Action: Clinicians should not prescribe anti-reflux
	medications
	Benefit: Avoid adverse events from unproven therapy
	Benefit: reduce cost
	Benefit: limit unnecessary treatment
	Risk/Harm: Potential withholding of therapy from
	patients who may benefit
	Evidence Quality: Grade B

Recommendation Strength: Recommendation against prescribing based on randomized trials with limitations and observational studies with a preponderance of harm over benefit. **Logic:** If for patients with hoarseness AND without signs of gastroesophageal reflux disease (GERD) AND without

symptoms of gastroesophageal reflux disease (GERD) Then Clinicians should not prescribe anti-reflux medications **Cost:** None

RECOMMENDATION: STATEMENT 5B. ANTI-REFLUX MEDICATION AND CHRONIC LARYNGITIS.

Conditional:	Clinicians may prescribe anti-reflux medication for patients
	with hoarseness and signs of chronic laryngitis.
	Decision Variable: patients with hoarseness
	Decision Variable: signs of chronic laryngitis
	Action: Clinicians may prescribe anti-reflux medication
	Benefit: Improved outcomes
	Benefit: promote resolution of laryngitis
	Risk/Harm: Adverse events related to anti-reflux
	medications
	Evidence Quality: Grade C
	Recommendation Strength: Option based on observational
	studies with limitations and a relative balance of benefit and
	harm
	Logic: If patients with hoarseness AND signs of chronic
	laryngitis Then Clinicians may prescribe anti-reflux
	medication
	Cost: Direct cost of medications

RECOMMENDATION: STATEMENT 6. CORTICOSTEROID THERAPY

Imperative:	Clinicians should not routinely prescribe oral corticosteroids
	to treat hoarseness
	Directive: Clinicians should not routinely prescribe oral
	corticosteroids to treat hoarseness
	Benefit: Avoid potential adverse events associated with
	unproven therapy
	Risk/Harm: None
	Evidence Quality: Grade B
	Recommendation Strength: Recommendation against
	prescribing based on randomzied trials showing adverse
	events and absence of clinical trials demonstrating benefits
	with a preponderance of harm over benefit for steroid use
	Flexibility: Intentional vagueness: Use of the word "routine"
	to acknowledge there may be specific situations, based on
	laryngoscopy results or other associated conditions, that may

justify steroid use on an individualized basis Logic: If {Inclusion Criterion: Hoarseness (dysphonia) } Then Clinicians should not routinely prescribe oral corticosteroids to treat hoarseness Cost: None

RECOMMENDATION: STATEMENT 7. ANTIMICROBIAL THERAPY

Imperative: Clinicians should not routinely prescribe antibiotics to treat hoarseness. **Directive:** Clinicians should not routinely prescribe antibiotics to treat hoarseness. **Benefit:** Avoidance of ineffective therapy with documented adverse events Risk/Harm: Potential for failing to treat bacterial, fungal, or mycobacterial causes of hoarseness Evidence Ouality: Grade A **Recommendation Strength:** Strong recommendation against prescribing prescribing based on systematic reviews and randomized trials showing ineffectiveness of antibiotic therapy and a preponderance of harm over benefit Flexibility: Intentional vagueness: The word "routine" is used in the boldface statement {clinicans should not routinely prescribe antibiotics to treat hoarseness} to discourage empiric therapy yet to acknowledge there are occasional circumstances where antibiotic use may be appropriate **Logic:** If {Inclusion Criterion: Hoarseness (dysphonia) } Then Clinicians should not routinely prescribe antibiotics to treat hoarseness.

RECOMMENDATION: STATEMENT 8A. LARYNGOSCOPY PRIOR TO VOICE THERAPY

Conditional:	Clinicians should visualize the larynx before prescribing
	voice therapy and document/communicate the results to the
	speech-language pathologist.
	Decision Variable: before prescribing voice therapy
	Action: Clinicians should visualize the larynx
	Benefit: Avoid delay in diagnosing laryngeal
	conditions not treatable with voice therapy
	Benefit: optimize voice therapy by allowing targeted
	therapy
	Risk/Harm: Delay in initiation of voice therapy
	Action: clinicians should document/communicate the results
	to the speech-language pathologist
	Benefit: Avoid delay in diagnosing laryngeal
	conditions not treatable with voice therapy
	Benefit: optimize voice therapy by allowing targeted
	therapy

	Risk/Harm: Delay in initiation of voice therapy
	Evidence Quality: Grade C
	Recommendation Strength: Recommendation based on
	observational studies showing benefit and a preponderance of
	benefit over harm
	Logic: If before prescribing voice therapy Then Clinicians
	should visualize the larynx AND clinicians should
	document/communicate the results to the speech-language
	pathologist
	Cost: Cost of the laryngoscopy and associated clinician visit
RECOMMENDATIO	JN: STATEMENT 8B. ADVOCATING FOR VOICE THERAPY
Conditional:	Clinicians should advocate voice therapy for patients
	diagnosed with hoarseness (dysphonia) that reduces voice-
	related quality of life (QOL).
	Decision Variable: patients diagnosed with hoarseness
	(dysphonia) that reduces voice-related QOL {Quality of Life}
	Action: Clinicians should advocate voice therapy
	Benefit: Improve voice-related QOL
	Benefit: prevent relapse
	Benefit: potentially prevent need for more invasive
	therapy
	Risk/Harm: No harm reported in controlled trials
	Evidence Quality: Grade A
	Recommendation Strength: Strong recommendation based
	on systematic reviews and randomized trials with a
	Floribility Intentional responses Desiding which notion to
	Flexibility: Intentional vagueness: Deciding which patients
	win benefit from voice therapy is often determined by the
	voice inerapist. The guideline panel elected to use a
	tracting aliniaian should advagate voice thereasy
	Leading childran should advocate voice therapy
	reduces voice related OOL (Ovality of Life) Then Clinicians
	should advocate voice therapy
	Cost: Direct cost of treatment
RECOMMENDATIO	ON: STATEMENT 9. SURGERY

Conditional:	Clinicians should advocate for surgery as a therapeutic option in patients with hoarseness with suspected: 1) laryngeal malignancy, 2) benign laryngeal soft tissue lesions, or 3) glottic insufficiency
	Decision Variable: patients with hoarseness Decision Variable: suspected laryngeal malignancy Decision Variable: suspected benign laryngeal soft tissue lesions

Decision Variable: suspected glottic insufficiency Action: Clinicians should advocate for surgery as a therapeutic option Benefit: Potential for improved voice outcomes in carefully selected patients Cost: Cost: None Risk/Harm: None Evidence Quality: Grade B Recommendation Strength: Recommendation based on observational studies demonstrating a benefit of surgery in these conditions and a preponderance of benefit over harm Logic: If patients with hoarseness AND (suspected laryngeal malignancy OR suspected benign laryngeal soft tissue lesions OR suspected glottic insufficiency) Then Clinicians should advocate for surgery as a therapeutic option Cost: None **RECOMMENDATION: STATEMENT 10. BOTULINUM TOXIN Conditional:** Clinicians should prescribe, or refer the patient to a clinician who can prescribe, botulinum toxin injections for the treatment of hoarseness caused by spasmodic dysphonia Decision Variable: for the treatment of hoarseness caused by spasmodic dysphonia Action: Clinicians should prescribe botulinum toxin injections **Benefit:** Improved voice quality and voice-related QOL {Quality of Life} Risk/Harm: Risk of aspiration and airway obstruction Action: Clinicians should refer the patient to a clinician who can prescribe botulinum toxin injections Benefit: Improved voice quality and voice-related QOL {Quality of Life} Risk/Harm: Risk of aspiration and airway obstruction Evidence Quality: Grade B Recommendation Strength: Recommendation based on randomized controlled trials with minor limitations and preponderance of benefit over harm. Logic: If for the treatment of hoarseness caused by spasmodic dysphonia Then Clinicians should prescribe botulinum toxin injections OR Clinicians should refer the patient to a clinician who can prescribe botulinum toxin injections Cost: Direct costs of treatment, time off work, and indirect costs of repeated treatments

RECOMMENDATION: STATEMENT 11. PREVENTION

Imperative: Clinicians may educate/counsel patients with hoarseness

about control/preventive measures
Directive: Clinicians may educate/counsel patients with
hoarseness about control/preventive measures
Benefit: Possible prevention of hoarseness in high-risk
persons
Risk/Harm: None
Evidence Quality: Grade C
Recommendation Strength: Option based on observational
studies and small randomized trials of poor quality
Logic: If {Inclusion Criterion: Hoarseness (dysphonia) }
Then Clinicians may educate/counsel patients with hoarseness
about control/preventive measures
Cost: Cost of vocal training sessions

ALGORITHM: